Abstract: The present invention relates to a bis phenyl hexa triene derivative, a preparation method thereof and a composition for skin whitening comprising the same as an active ingredient. The said derivative inhibits the expression of tyrosinase, TRP 1 (tyrosinase-related protein 1), TRP 2 (tyrosinase-related protein 2) or MITF (microphthalmia-associated transcription factor) gene which produces a precursor necessary for the generation of melanin, suppresses the activity of tyrosinase, eventually inhibits the biosynthesis of melanin, is safe due to low cytotoxicity, and has less side effects and excellent antioxidative effect, so that it can be effectively used as a composition for skin whitening.

Abstract: The invention relates to a composition for reducing fatty tissue including at least one non-ionic surfactant as an active substance for reducing fatty tissue, wherein said non-ionic surfactant is polidocanol and the solvent is water, and a method for reducing unwanted fatty tissue by administering the composition.

Abstract: Disclosed is a topical composition for the treatment of hirsutism comprising capryloyl glycine as active ingredient, mixed with dermatologically acceptable carriers.

Abstract: Described herein is a shampoo composition and methods of using the same, the shampoo composition including a copper chelant, a detersive surfactant, and a carrier.

Abstract: The instant disclosure relates hair care compositions comprising ionic liquids or ionic mixtures. Ionic liquids or ionic mixtures are combined with a cosmetically acceptable carrier to form ready-to-use hair care compositions. The ionic liquids and the ionic mixtures are formed from; (1) thiolactic acid and/or one or more alkali metal or alkaline earth metal salts thereof; and (2) one or more amine compounds, and/or one or more ammonium cationic compounds, and/or one or more salts thereof. The ionic liquids, the ionic mixtures, and the hair care compositions comprising the ionic liquids or the ionic mixtures, are useful in methods for preventing hair damage, shaping hair, caring for hair, etc.

Abstract: The present invention relates to a process for dyeing and relaxing curls of keratin fibres, such as the hair, which comprises the application to the fibres of one or more acidic compositions comprising reducing agents and of one or more compositions comprising hair-dyeing agents, and a step of heat treatment of the fibres by means of a heating tool. A subject of the invention is also the use of the composition(s) comprising reducing agents and of the composition(s) comprising hair-dyeing agents in a process for dyeing and relaxing curls of keratin fibres. Finally, a subject of the invention is a multi-compartment device or “kit” suitable for carrying out such a process.

Abstract: The invention provides a method for the topical non therapeutical cosmetic treatment of the scalp comprising applying to the scalp an effective amount of at least one alkyl-phthalide or a plant extract comprising mainly said alkyl-phthalide. In particular, the treatment is an anti-dandruff treatment. According to the invention, a CO2 supercritical extract of Apium graveolens seeds consisting mainly of sedanenolide may be used.

Abstract: A human growth hormone fusion protein has enhanced thermal stability. The human growth hormone fusion protein has the amino acid sequence SEQ ID NO: 3 or SEQ ID NO: 4. A gene encoding the human growth hormone fusion protein has E. coli codon-optimized nucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 6. A recombinant vector includes the aforementioned gene. A host cell is transformed with the aforementioned recombinant vector. A method for producing in a host cell a human growth hormone fusion protein includes transforming a host cell with the aforementioned recombinant vector. The human growth hormone fusion protein may improve skin wrinkle and maintain skin elasticity. As the human growth hormone fusion protein has thermal stability and also has an effect of improving skin wrinkle and increasing the effect of maintaining skin elasticity, it can be advantageously used as a raw material of cosmetics.

Abstract: The present disclosure relates to an external-use skin preparation composition containing a natural ceramide, a ceramide derivative, and a Hibisci cortex extract, and more specifically, the present disclosure relates to an external-use skin preparation composition containing these ingredients, thereby being effective for enhancing skin moisturizing ability, reducing skin wrinkles, and enhancing elasticity. In addition, the present disclosure relates to use of the composition, and a method for improving skin moisturization, reducing skin wrinkles, and/or improving skin elasticity by using the composition.

Abstract: A powdery cosmetic composition in the form of a compacted powder including, in a physiologically acceptable medium, (i) a pulverulent phase including nanocrystalline cellulose, and (ii) a binder phase. Also, the use of the pulverulent phase for the preparation of a cosmetic composition in the form of compacted powder with satisfactory cohesive properties.

Abstract: A photopolymerizable composition for forming a photopolymerized nail top coating of a substantially uniform mixture of ethyl cellulose and crosslinked (meth)acrylate polymer is disclosed.

Abstract: The present invention relates to a composition for treating keratin fibres, comprising at least an aqueous dispersion of hybrid hydrophobic film-forming acrylic polymer particles, at least one linear block silicone copolymer and at least one amino acid or amino acid derivative.

Abstract: A composition for providing a film on keratin fibres, the composition comprising: a film-forming aminosilicone polymer; a silicone resin; an ether of a water-soluble polyhydric alcohol; a thickening system comprising a deposition enhancer and a thickening polymer; one or more coloured materials or one or more pigments; water; 2-phenoxyethanol and/or phenylmethanol; wherein the composition is substantially free of esters of parahydroxybenzoic acid; and wherein the composition is substantially free of isothiazolinone compounds. Also, associated methods, kits and uses.

Abstract: Disclosed are compositions, systems and methods for treating keratinous fibers such as hair. The compositions and systems comprise an oxazoline functionalized polymer and a carboxyl group-containing polymer. The compositions and methods are employed to improve the quality of the keratinous fibers.

Abstract: A skin cleansing composition has from about 0.05% to about 15%, by weight of the composition, of a plurality of color stable abrasive particles comprising a non-oxide colorant; and an antioxidant selected from the group consisting of tocopherol acetate (Vitamin E Acetate), butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), sodium benzotriazolyl butylphenol sulfate, Vitamin C (ascorbic acid) and combinations thereof. The abrasive particles are sustainable. The skin cleansing composition has a pH of <6 or from about 4 to about 6.

Abstract: The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. In certain embodiments, the programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, and volume of gastric fluid. The programmable osmotic-controlled oral compositions of the disclosure comprise a multilayer core comprising a drug for controlled release, wherein the core is coated with a semipermeable membrane comprising an orifice and, optionally, an immediate release coating, comprising a drug for immediate release, over the semipermeable membrane. The multilayered core comprises a pull layer containing the drug and a push layer.

Abstract: The present invention provides a conductive hydrogel comprising a polystyrene sulfonate compound selected from poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS), reduced graphene oxide polystyrene sulfonate (rGO:PSS) and rGO:PEDOT:PSS; and a conjugate of polyethylene glycol (PEG) and a linker-(BX)n oligopeptide of formula (I) PEG-linker-(BX)n??(I) wherein B is lysine or arginine, X is selected from alanine, glycine, serine, threonine, tyrosine, glutamic acid or aspartic acid and n is an integer selected from 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20. The invention further relates to processes for assembling the conductive hydrogel. The conductive hydrogel can be used in various biomedical applications, such as neuroprostheses, biosensors, nerve grafts, cell culture and encapsulation of cells and microorganisms as well as for drug delivery.

Abstract: The invention relates to pharmacology and to a composition for making an antitumor agent in the form of a solution for injection. The composition contains alloferon at a concentration of 0.05 to 0.1% wt, cis-diamminedichloridoplatinum at a concentration of 0.01 to 0.05% wt, and water. The composition of the present invention features antitumor activity and hypotoxicity. 1 Figure, 3 Tables, 5 examples.

Abstract: The invention pertains to liposomes containing an oil-in-water emulsion of a selected combination of at least ten different essential plant oils produced with phospholipids found in human membranes and methods for treating respiratory diseases, disorders or conditions by administering the liposomes into the nose and respiratory system.

Abstract: The present invention relates to a chewing gum for mucosal delivery of cannabinoids, the chewing gum including water-soluble chewing gum ingredients and water-insoluble gum base, wherein the gum base has one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the water-soluble chewing gum ingredients include one or more sugar alcohols in an amount of 35-80% by weight of the chewing gum, and wherein the chewing gum has one or more cannabinoids.

Abstract: The present invention provides a parenteral dosage form consisting essentially of a solution filled in a container, the solution comprising amiodarone or its pharmaceutically acceptable salt and a sulfo-alkyl ether beta-cyclodextrin in an aqueous vehicle, wherein the solution has a pH in the range of about 2.4 to 3.9 and further wherein the dosage form is sterilized by subjecting the filled container to autoclaving.

Abstract: An orally administrable micellar composition is provided. The composition comprises a pharmaceutical agent encapsulated in micelles formed by at least one micelle-forming compound in a pharmaceutically acceptable aqueous solvent comprising an alkali metal salicylate and a pharmaceutically acceptable edetate combined with at least one physiologically acceptable film forming agent.

Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

Abstract: The present invention relates to a method for preparing viral vector-based compositions wherein the viral vector-based particles present in the composition have a particle size distribution with a polydispersity index (PDI) of less than 0.5, the method comprising the steps: (a) providing replication-deficient viral vectors; (b) providing a solution comprising at least one sugar and at least three different excipients selected from hydrophilic and amphiphilic excipients, wherein the excipients are characterized by polar, aliphatic, aromatic, negatively charged, and/or positively charged functional groups, and wherein the solution is further characterized by an excipient-sugar ratio of at least 1:2 (w/w); and (c) mixing the replication deficient viral vectors of step (a) with the solution of step (b).

Abstract: Disclosed herein is a carbon quantum dot produced by the step of subjecting dopamine and spermine to a pyrolysis treatment at 250° C. Also disclosed herein is use of the carbon quantum dot for treating a bacterial infection, and for inhibiting bacterial growth and biofilm formation.

Abstract: The present invention relates to a novel directly compressible matrix for the production of tablets which disintegrate rapidly in the presence of moisture, in particular in the mouth.

Abstract: There is provided low-substituted hydroxypropyl cellulose (L-HPC) having good bindability, anti-capping performance and disintegratability. More specifically, there are provided L-HPC having a hydroxypropoxy group content of 5 to 16% by mass and a volume fraction of long fibrous particles of more than 50.0% relative to all of L-HPC particles which are classified, on a basis of dynamic image analysis, into fine particles, spherical particles, the long fibrous particles and short fibrous particles; and a solid preparation containing the L-HPC.

Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising Ibuprofen using solventless mixing methods. Excess coating material that is not bound to coated Ibuprofen may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Additionally, the compositions can be formulated to preserve the functional coating of coated Ibuprofen and to minimize aeration of Ibuprofen when mixed into suspension.

Abstract: The devices, methods, and compositions disclosed herein accomplish robust cell encapsulation in polymer microparticles using a vertically oriented microfluidic device. A hydrophilic polymer precursor solution is flowed into a first inlet channel, which extends inward from an upper surface of the device housing. A hydrophobic fluid is flowed into a second inlet channel, which extends inward from a lower surface of the device housing. The two inlet channels meet at a junction, and an outlet channel extends away from the two inlet channels. When the two inwardly flowing streams meet at the junction, the polymer precursor solution disperses into the hydrophobic fluid. The dispersed precursor droplets are photopolymerized into microparticles as they travel through the outlet channel. The resulting microparticles are highly uniform, and are larger than conventionally formed microparticles. Cells of varying types can be encapsulated with high viability and spatial uniformity.

Abstract: The present invention provides a patch comprising a backing layer and an adhesive agent layer, wherein the adhesive agent layer is non-aqueous, the adhesive agent layer contains nonylic acid vanillylamide, terpene-based resin, rosin-based resin, styrene-isoprene-styrene block copolymer, and liquid paraffin, a mass ratio of a content of the terpene-based resin to a content of the rosin-based resin ((content of the terpene-based resin)/(content of the rosin-based resin)) in the adhesive agent layer is 0.45 to 1.3, and a mass ratio of a content of the styrene-isoprene-styrene block copolymer to a content of the liquid paraffin ((content of the styrene-isoprene-styrene block copolymer)/(content of the liquid paraffin)) in the adhesive agent layer is 0.45 to 1.2.

Abstract: The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of hyperhidrosis.

Abstract: The present invention relates to a ready-to-administer parenteral dosage form of norepinephrine which comprises an aqueous solution of norepinephrine, having an anti-oxidant which is not a sulfite anti-oxidant, wherein the dosage form is stable at room temperature for prolonged period of time.

Abstract: This invention relates to therapeutic compounds and compositions, and methods for their use in the prevention or treatment of neurological disorders. In particular, the invention relates to N-methyl-D-aspartate receptor (NMDAR) allosteric modulators and methods for their use in the prevention or treatment of disorders or conditions caused by or related to NMDAR dysfunctions. The invention also relates to a method for identifying NMDAR allosteric modulators.

Abstract: Improved methods and compositions are disclosed for treating dry eye by administering intranasally a therapeutically effective amount of a capsaicinoid compound embedded in multiple layers of solid lamellar crystals of monoglycerides to patients with deficient tear production. The lipophilic capsaicinoid drug is embedded in multiple layers of solid lamellar crystals of monoglycerides, and these crystals are incorporated into pharmaceutically acceptable vehicles comprised of solutions, suspensions, foams, creams, ointments, and gels. The resulting formulations of the capsaicinoid are more stable, less irritating to skin and mucous membranes, and provide increased and more controlled release of the capsaicinoid compound.

Abstract: A method of protecting a host from an enteric toxigenic pathogen comprises administering a salicylanilide to the host. A method of reducing virulence of an enteric toxigenic pathogen comprises administering a salicylanilide to a host infected with or at risk of infection with pathogen. A method of reducing recurrence of an infection caused by an enteric toxigenic pathogen, comprises administering a salicylanilide to a host previously infected with the pathogen.

Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.

Abstract: The invention relates to a compound for use in a method of treatment or prevention of migraine and/or symptoms thereof. The compound is selected from beta-hydroxybutyric acid (?HB) or a pharmaceutically acceptable salt thereof, acetoacetate (AcAc) or a pharmaceutically acceptable salt thereof, a metabolic precursor of ?HB or AcAc 1,3-butanedio and a compound comprising an acetoacetyl- or 3-hydroxybutyrate moiety. The invention further relates to a pharmaceutical composition comprising ?HB, AcAc or a pharmaceutically acceptable salt thereof.

Abstract: The present invention is directed toward fatty acid-based particles, and methods of making such particles. The particles can be associated with an additional, therapeutic agent. Also provided herein is a method of forming fatty acid particles, comprising associating a cross-linked, fatty acid-derived biomaterial with a cryogenic liquid; and fragmenting the bio material/cryogenic liquid composition, such that fatty acid particles are formed. The particles can be used for a variety of therapeutic applications.

Abstract: Methods are provided of identifying a subject having impaired aldehyde dehydrogenase activity; and administering to the subject a compound comprising an isotopically-modified polyunsaturated fatty acid, an isotopically-modified polyunsaturated fatty acid ester, an isotopically-modified polyunsaturated fatty acid thioester, an isotopically-modified polyunsaturated fatty acid amide, a polyunsaturated fatty acid mimetic, or an isotopically-modified polyunsaturated fatty acid pro-drug, the compound having an isotopic modification that reduces oxidation of the compound, thereby reducing production in the subject of substrate for aldehyde dehydrogenase. Some aspects provide coadministering an isotopically-modified polyunsaturated fatty acid and an oxylipin.

Abstract: The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.

Abstract: The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).

Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful for use as prebiotic in a subject; for the modulation of the microbiota composition; for enhancing the population of good bacteria like Akkermansia muciniphila and for enhancing the efficacy of cancer immunotherapy of a subject. These compounds and compositions comprise at least one compound chosen from formula (I), (II), (III), (IV).

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy including baicalein as an active ingredient. Baicalein is capable of regulating thymic stromal lymphopoietin-mediated signal transduction. The pharmaceutical composition of the present invention can effectively suppress inflammatory responses of allergic or asthmatic diseases due to the presence of baicalein extracted from Scutellariae Radix that regulates TSLP-mediated intracellular signal transduction to inhibit intracellular phosphorylation of STATS and inhibit the binding of TSLP to TSLPR. In addition, the pharmaceutical composition of the present invention may further include one or more compounds having synergistic effects with baicalein. In this case, the pharmaceutical composition can more effectively suppress inflammatory responses of allergic diseases such as asthma or atopy.

Abstract: A pouch designed for administration of an active ingredient in the oral cavity is disclosed, the pouch containing an amount of one or more cannabinoids. Also, pouches for use as a medicament, for use in alleviation of pain, and for use in mitigation of appetite deficiency are disclosed. Further, a method of alleviation of pain and a method of mitigation of appetite deficiency using the pouch are disclosed.

Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Abstract: Provided is an external composition excellent in stability and impression from use. An external composition containing (A) at least one member selected from the group consisting of ascorbic acid and salts of ascorbic acid, (B) at least one member selected from the group consisting of 3-O-ethylascorbic acid, salts of 3-O-ethylascorbic acid, and hydroxylated lecithin, and (C) polyethylene glycol is prepared.

Abstract: Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.

Abstract: Methods of inducing bradycardia (slowing a heart rate) in a subject in need thereof, treating a medical condition in which inducing bradycardia (slowing a heart rate) is desirable or beneficial in a subject in need thereof and/or treating a medical condition associated with cardiac arrhythmia, are provided. The methods are effected by blocking SK4 channel in SAN cell of the subject and/or by administering to the subject a therapeutically effective amount of a blocker of an SK4 channel. A method of identifying candidate compounds for treating an arrhythmic cardiac disorder, by identifying compounds that reduce a pacing rate of the SAN cells is also provided.